Biologic therapies in type 1 diabetes: how far are they from us?

Chin Med J (Engl). 2013 Nov;126(21):4003-5.

Authors

Chao Deng¹, Yu-Fei Xiang, Zhi-Guang Zhou

Affiliation

¹ Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, China.

PMID: 24229664

No abstract available

Publication types

Editorial

MeSH terms

Abatacept
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Biological Therapy / methods*
Diabetes Mellitus, Type 1 / drug therapy*
Humans
Immunoconjugates / therapeutic use
Rituximab

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Immunoconjugates
Rituximab
Abatacept
otelixizumab
teplizumab